IBDEI045 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,1409,2)
 ;;=^5008725
 ;;^UTILITY(U,$J,358.3,1410,0)
 ;;=K70.10^^3^41^25
 ;;^UTILITY(U,$J,358.3,1410,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1410,1,3,0)
 ;;=3^Alcoholic hepatitis without ascites
 ;;^UTILITY(U,$J,358.3,1410,1,4,0)
 ;;=4^K70.10
 ;;^UTILITY(U,$J,358.3,1410,2)
 ;;=^5008785
 ;;^UTILITY(U,$J,358.3,1411,0)
 ;;=K73.0^^3^41^45
 ;;^UTILITY(U,$J,358.3,1411,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1411,1,3,0)
 ;;=3^Chronic persistent hepatitis, not elsewhere classified
 ;;^UTILITY(U,$J,358.3,1411,1,4,0)
 ;;=4^K73.0
 ;;^UTILITY(U,$J,358.3,1411,2)
 ;;=^5008811
 ;;^UTILITY(U,$J,358.3,1412,0)
 ;;=N12.^^3^41^104
 ;;^UTILITY(U,$J,358.3,1412,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1412,1,3,0)
 ;;=3^Tubulo-interstitial nephritis, not spcf as acute or chronic
 ;;^UTILITY(U,$J,358.3,1412,1,4,0)
 ;;=4^N12.
 ;;^UTILITY(U,$J,358.3,1412,2)
 ;;=^5015575
 ;;^UTILITY(U,$J,358.3,1413,0)
 ;;=N30.90^^3^41^51
 ;;^UTILITY(U,$J,358.3,1413,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1413,1,3,0)
 ;;=3^Cystitis, unspecified without hematuria
 ;;^UTILITY(U,$J,358.3,1413,1,4,0)
 ;;=4^N30.90
 ;;^UTILITY(U,$J,358.3,1413,2)
 ;;=^5015642
 ;;^UTILITY(U,$J,358.3,1414,0)
 ;;=N30.91^^3^41^50
 ;;^UTILITY(U,$J,358.3,1414,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1414,1,3,0)
 ;;=3^Cystitis, unspecified with hematuria
 ;;^UTILITY(U,$J,358.3,1414,1,4,0)
 ;;=4^N30.91
 ;;^UTILITY(U,$J,358.3,1414,2)
 ;;=^5015643
 ;;^UTILITY(U,$J,358.3,1415,0)
 ;;=N34.1^^3^41^83
 ;;^UTILITY(U,$J,358.3,1415,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1415,1,3,0)
 ;;=3^Nonspecific urethritis
 ;;^UTILITY(U,$J,358.3,1415,1,4,0)
 ;;=4^N34.1
 ;;^UTILITY(U,$J,358.3,1415,2)
 ;;=^5015655
 ;;^UTILITY(U,$J,358.3,1416,0)
 ;;=N39.0^^3^41^107
 ;;^UTILITY(U,$J,358.3,1416,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1416,1,3,0)
 ;;=3^Urinary tract infection, site not specified
 ;;^UTILITY(U,$J,358.3,1416,1,4,0)
 ;;=4^N39.0
 ;;^UTILITY(U,$J,358.3,1416,2)
 ;;=^124436
 ;;^UTILITY(U,$J,358.3,1417,0)
 ;;=N41.9^^3^41^74
 ;;^UTILITY(U,$J,358.3,1417,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1417,1,3,0)
 ;;=3^Inflammatory disease of prostate, unspecified
 ;;^UTILITY(U,$J,358.3,1417,1,4,0)
 ;;=4^N41.9
 ;;^UTILITY(U,$J,358.3,1417,2)
 ;;=^5015694
 ;;^UTILITY(U,$J,358.3,1418,0)
 ;;=N45.1^^3^41^58
 ;;^UTILITY(U,$J,358.3,1418,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1418,1,3,0)
 ;;=3^Epididymitis
 ;;^UTILITY(U,$J,358.3,1418,1,4,0)
 ;;=4^N45.1
 ;;^UTILITY(U,$J,358.3,1418,2)
 ;;=^41396
 ;;^UTILITY(U,$J,358.3,1419,0)
 ;;=N70.93^^3^41^94
 ;;^UTILITY(U,$J,358.3,1419,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1419,1,3,0)
 ;;=3^Salpingitis and oophoritis, unspecified
 ;;^UTILITY(U,$J,358.3,1419,1,4,0)
 ;;=4^N70.93
 ;;^UTILITY(U,$J,358.3,1419,2)
 ;;=^5015808
 ;;^UTILITY(U,$J,358.3,1420,0)
 ;;=N70.91^^3^41^95
 ;;^UTILITY(U,$J,358.3,1420,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1420,1,3,0)
 ;;=3^Salpingitis, unspecified
 ;;^UTILITY(U,$J,358.3,1420,1,4,0)
 ;;=4^N70.91
 ;;^UTILITY(U,$J,358.3,1420,2)
 ;;=^5015806
 ;;^UTILITY(U,$J,358.3,1421,0)
 ;;=N70.92^^3^41^84
 ;;^UTILITY(U,$J,358.3,1421,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1421,1,3,0)
 ;;=3^Oophoritis, unspecified
 ;;^UTILITY(U,$J,358.3,1421,1,4,0)
 ;;=4^N70.92
 ;;^UTILITY(U,$J,358.3,1421,2)
 ;;=^5015807
 ;;^UTILITY(U,$J,358.3,1422,0)
 ;;=N73.9^^3^41^59
 ;;^UTILITY(U,$J,358.3,1422,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,1422,1,3,0)
 ;;=3^Female pelvic inflammatory disease, unspecified
 ;;^UTILITY(U,$J,358.3,1422,1,4,0)
 ;;=4^N73.9
 ;;^UTILITY(U,$J,358.3,1422,2)
 ;;=^5015820
 ;;
 ;;$END ROU IBDEI045
